The global Viral Vector-Based Gene Therapy market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

United States market for Viral Vector-Based Gene Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Viral Vector-Based Gene Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Viral Vector-Based Gene Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Viral Vector-Based Gene Therapy players cover Sibiono, Rigvir Group, Shanghai Pharma (Sunway), Amgen, Spark Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information) newest research report, the ?Viral Vector-Based Gene Therapy Industry Forecast? looks at past sales and reviews total world Viral Vector-Based Gene Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Viral Vector-Based Gene Therapy sales for 2025 through 2031. With Viral Vector-Based Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector-Based Gene Therapy industry.

This Insight Report provides a comprehensive analysis of the global Viral Vector-Based Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector-Based Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Viral Vector-Based Gene Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector-Based Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector-Based Gene Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector-Based Gene Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Adenovirus (AdV)
    Adeno-associated Virus (AAV)

Segmentation by Application:

    Hospital
    Clinic
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Sibiono
    Rigvir Group
    Shanghai Pharma (Sunway)
    Amgen
    Spark Therapeutics
    Novartis Gene Therapies
    Daiichi Sankyo
    PTC Therapeutics